Propanc Health Group Corporation — Form 10-Q Summary
Reporting period: Three months ended September 30, 2014; comparative results are for the three months ended September 30, 2013. The filing identifies the issuer as Propanc Health Group Corporation, not Propanc Biopharma, Inc. Financial statements are unaudited.
Business context and financial performance
The company is a development-stage research and development business focused on cancer treatments. Its lead product was in preclinical development; the company reported no products at the clinical-trial stage and no revenue during either comparative quarter.
| Metric | Quarter ended Sep. 30, 2014 | Quarter ended Sep. 30, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $238,138 | $308,571 |
| Operating loss | $238,138 | $308,571 |
| Interest expense | $548,479 | $2,165 |
| Net loss | $783,300 | $571,511 |
| Net loss per share | $0.01 | $0.01 |
| Cash used in operating activities | $99,811 | $75,184 |
| Cash provided by financing activities | $16,139 | $113,218 |
Gross margin is not applicable because there was no revenue. No income tax benefit was recorded. Research and development expense was $3,879, versus zero in the prior-year quarter; management said R&D spending had remained minimal while the company sought capital.
Liquidity, debt and capital structure
- At September 30, cash was $4,513, total current assets were $51,572, and current liabilities were $1,835,953. The resulting working-capital deficit was $1,784,381; stockholders’ deficit was also $1,784,381. The accumulated deficit was $18,336,217.
- Current liabilities included $979,312 of debt settlement payable in stock, $325,794 of convertible notes, $50,000 of notes payable, and $65,915 of derivative liabilities. The filing also reports director/officer loans, including $46,240 of loans past due and in default.
- Operating cash use increased from $75,184 to $99,811. Cash declined from $87,799 at June 30, 2014 to $4,513 at September 30.
- Common shares outstanding increased from 72,684,767 at June 30 to 82,794,100 at September 30. The filing reports 90,955,100 shares outstanding as of November 19, 2014.
Material changes, outlook and risks
- Net loss increased by $211,789 year over year, primarily because of the sharp increase in interest and settlement-related charges. Management attributes much of the interest expense to a settlement premium; the filing also reports a $405,002 loss on settlement in the cash-flow reconciliation.
- A July 2014 settlement transferred approximately $627,998 of creditor liabilities to a purchaser. A court order and purchaser fee resulted in an obligation to issue approximately $1.033 million of common stock. The company issued 7,426,000 shares in September; a further 8,161,000 shares were issued on November 4, 2014.
- A separate equity purchase agreement permits the company, subject to contractual restrictions including a floor price and ownership limit, to sell up to $5 million of stock over a commitment period of up to 24 months. This is a financing arrangement, not assurance that the full amount will be raised.
- Management stated that available cash and committed resources were insufficient to meet obligations over the next 12 months. The filing says the losses, cash needs, working-capital deficit and dependence on future financing raise substantial doubt about the company’s ability to continue as a going concern. There is no assurance that financing, patent progress, product development or adequate future sales will be achieved.
- Management described efforts to advance patent filings, publish scientific discoveries and negotiate with third parties to raise capital. Patents had been granted in South Africa and New Zealand; applications and protections elsewhere remained pending or in progress. No quantified operating or financial guidance was provided.
- Disclosure controls and procedures were reported as ineffective because the small staff prevented adequate segregation of duties. Management said it planned to address the weakness by hiring accounting personnel when resources permitted.
Important facts for investors to verify
- Confirm the issuer and period: this filing is for Propanc Health Group Corporation and the quarter ended September 30, 2014.
- Review the settlement, stock issuance schedule, share-sale proceeds distributed to creditors, and the dilution reflected in subsequent share counts.
- Check the terms, availability and actual use of the equity purchase agreement and other financing; the filing does not establish that the stated $5 million capacity will be funded.
- Assess near-term cash needs, defaulted or past-due obligations, and the company’s stated going-concern uncertainty.
- Track clinical-development progress, R&D funding and patent outcomes; the lead product remained preclinical, with no revenue reported.